REVOLADETM  (eltrombopag) is indicated for the treatment of

  • Chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients is 1 year and above who are refractory to other treatments (e.g. Corticosteroids, immunoglobulins).
  • Adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia where the degree thrombocytopenia is the main factor preventing the initiation or the limiting the ability to maintain optimal interferon-based therapy.
  • Adult patients require severe aplastic anaemia (SAA) who were either refractory to prior immune suppressive therapy or heavily pretreated and are unsuitable haematopoietic stem cell transplantation.
Reference: 1. REVOLADE Summary of Product Characteristics. March 2016.